Principal Investigator
Wacharee Seeherunvong
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20210561
Clinical Trial Summary
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK)
Phase
Phase II
Funding Agency/Sponsor
Industry
Disease
Nephrology
Contact Information
Study Contact
Wacharee Seeherunvong
Phone Number
+1 (305) 5856726 x3480
Email
wseeherunvong@miami.edu